Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent.
Cyclooxygenase (COX) has two isoforms, COX-1 and -2, which catalyze the key step in the conversion of cellular arachidonic acid into prostaglandins. In recent years, interest in COX-2 has significantly increased since it has been a target for the development of specific non-steroidal anti-inflammatory drugs. We report that COX-2 expression is up-regulated in phorbol ester (phorbol myristate acetate, PMA)-differentiated human U937 macrophage-like cells stimulated with lipopolysaccharide (LPS), whereas COX-1 is not up-regulated. We show that the LPS-induced up-regulation of COX-2 depends on the activity of the Mg(+2)-dependent phosphatidic acid phosphohydrolase 1 (PAP-1). Inhibition of PAP-1 by bromoenol lactone, propranolol, or ethanol resulted in a decrease in LPS-induced COX-2 mRNA transcript production, COX-2 protein expression, and prostaglandin E(2) release from U937 macrophages. To ensure that these results did not arise because of PMA treatment of the U937 cells, similar experiments were conducted with the P388D(1) cell line, which does not require PMA differentiation. LPS increased the levels of endogenous cellular diacylglycerol (DAG) within 2 min of stimulation. This increase was observed to be sensitive to the PAP-1 inhibitors. Furthermore, phosphatidic acid phosphohydrolase activity assays showed that the bromoenol lactone-sensitive PAP-1 activity was translocated from the cytosolic fraction to the membrane fraction within 2 min of LPS exposure. Finally, DAG add-back experiments demonstrate that LPS-induced COX-2 expression is enhanced by the addition of exogenous DAG.
Grkovich
Andrej
A
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0601, USA.
Johnson
Christina A
CA
Buczynski
Matthew W
MW
Dennis
Edward A
EA
D000818:Animals; D000440:Butanols / Q000494:pharmacology; D051546:Cyclooxygenase 2 / Q000235:genetics*; D019610:Cytoprotection; D004075:Diglycerides / Q000096:biosynthesis; D015232:Dinoprostone / Q000096:biosynthesis; D000431:Ethanol / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects* / Q000201:enzymology*; D051379:Mice; D009281:Naphthalenes / Q000494:pharmacology; D000073718:Pancreatitis-Associated Proteins; D010711:Phosphatidate Phosphatase / Q000378:metabolism*; D011433:Propranolol / Q000494:pharmacology; D011753:Pyrones / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics; D013997:Time Factors; D020298:U937 Cells; D015854:Up-Regulation
D000440:Butanols; D004075:Diglycerides; D008070:Lipopolysaccharides; D009281:Naphthalenes; D000073718:Pancreatitis-Associated Proteins; D011753:Pyrones; C000612141:REG3A protein, human; D012333:RNA, Messenger; D000431:Ethanol; C068314:6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; D011433:Propranolol; D051546:Cyclooxygenase 2; D010711:Phosphatidate Phosphatase; D015232:Dinoprostone